MBX-2982 5 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
Search Results
MBX-2982 50 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
MBX-2982 25 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
Rac-Belinostat 200 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
Rac-Belinostat 25 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
MHY1485 10 mg | 97.74%
TargetMol
MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes.
More Information Supplier PageMHY1485
MHY1485 100 mg | 97.74%
TargetMol
MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes.
More Information Supplier PageMHY1485
Dabrafenib 5 mg | Purity Not Available
TargetMol
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).
More Information Supplier PageDabrafenib
Dabrafenib 50 mg | Purity Not Available
TargetMol
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).
More Information Supplier PageDabrafenib
Dabrafenib 10 mg | Purity Not Available
TargetMol
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).
More Information Supplier PageDabrafenib